Individual Patient Expanded Access for Use of Gilteritinib (ASP2215) for Patient Y.A.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2018 Status changed from recruiting to completed.
- 25 Oct 2017 New trial record